Skip to main content
Premium Trial:

Request an Annual Quote

Microbiotica, Genentech Ink IBD Alliance

This article has been updated to include additional details about the terms of the alliance.

NEW YORK (GenomeWeb) — Wellcome Sanger Institute spinout Microbiotica announced today that it has partnered with Genentech to develop biomarkers, targets, and medicines for inflammatory bowel disease (IBD).

Under the terms of the deal, Microbiotica will use its metagenomics microbiome platform — which comprises a microbiome culture collection and linked reference genome database — to analyze patient samples from clinical trials of Genentech's investigational IBD drugs to identify microbiome biomarker signatures of drug response, novel IBD drug targets, and live bacterial therapeutic products.

According to a Microbiotica spokesperson, Genentech will own any drug response biomarkers and drug targets resulting from the alliance. Microbiotica will develop the live bacterial therapeutics, which Genentech will have the option to commercialize.

In exchange, Microbiotica will receive an undisclosed upfront payment and stands to receive up to $534 million in research, development, and commercialization milestones. Microbiotica is also eligible to receive royalties on the sale of certain products resulting from the alliance, and be able to use the Genentech samples to expand its culture collection and reference genome database.

Additional terms were not disclosed.

"We believe the microbiome represents a new paradigm in biomedicine, both for understanding drug response and as a novel therapeutic modality," James Sabry, senior vice president and global head of partnering at Genentech, said in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.